Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regent Pacific GroupRPGLF 12 EV-to-FCF is -9.33 as of Jul. 15, 2026. GuruFocus rates RPGLF with a GF Score™ of 12/100. The stock has 7 warning signs investors should review. Among 564 Drug Manufacturers companies, Regent Pacific Group ranks worse than 177304.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Regent Pacific Group's Enterprise Value is $40.25 Mil.
Regent Pacific Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.31 Mil. Therefore, Regent Pacific Group's EV-to-FCF for today is -9.33.
The historical rank and industry rank for Regent Pacific Group's EV-to-FCF or its related term are showing as below:
RPGLF'
s EV-to-FCF Range Over the Past 10 Years
Min: -36.39 Med: -7.53 Max: 88.59
Current: -8.84
During the past 13 years, the highest EV-to-FCF of Regent Pacific Group was 88.59. The lowest was -36.39. And the median was -7.53.
RPGLF's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs RPGLF: -8.84
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regent Pacific Group (OTCPK:RPGLF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regent Pacific Group's PE Ratio (TTM) for today is calculated as:
Regent Pacific Group's share price for today is $0.0059.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Regent Pacific Group EV-to-FCF Related Terms
Regent Pacific Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Regent Pacific Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's EV-to-FCF falls into.
Regent Pacific Group's current Enterprise Value is $40.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regent Pacific Group (RPGLF) has a EV-to-FCF of -9.33 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Regent Pacific Group and its competitors. According to the industry distribution chart, Regent Pacific Group ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Regent Pacific Group's EV-to-FCF too high?
Regent Pacific Group's current EV-to-FCF is -9.33. Based on the distribution chart, Regent Pacific Group ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #999999 out of 564 companies for EV-to-FCF. This places Regent Pacific Group in the lower half of its industry. The industry median EV-to-FCF is 20.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current EV-to-FCF is -9.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current EV-to-FCF of -9.33. The current EV-to-FCF is -9.33. Regent Pacific Group's overall GF Score™ is 12/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current EV-to-FCF is -9.33 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
12GF Score
Get the complete analysis for RPGLF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
